Cyclin D1, EGFR, and Akt/mTOR pathway
Dimitrios Dionysopoulos(Aristotle University of Thessaloniki), George Fountzilas(Hellenic Cooperative Oncology Group), Ilias Karasmanis(Aristotle University of Thessaloniki), Konstantinos Markou(Aristotle University of Thessaloniki), Kitty Pavlakis(IASO General Hospital), Vassiliki Kotoula(Aristotle University of Thessaloniki), Elena Fountzilas(St. Luke's Hospital), Angelos Nikolaou(Aristotle University of Thessaloniki), Konstantine T. Kalogeras(Aristotle University of Thessaloniki), Nikolaos Angouridakis(Aristotle University of Thessaloniki)
Cited by 24
Related Papers
Review of precision cancer medicine: Evolution of the treatment paradigm
|Cancer Treatment Reviews|2020|747
Gene Expression Profile of <i>BRCA</i>ness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
|Journal of Clinical Oncology|2010|488
Clinical trial design in the era of precision medicine
|Genome Medicine|2022|279
Keap1 Mutations and Nrf2 Pathway Activation in Epithelial Ovarian Cancer
|Cancer Research|2011|266
Primary gastrointestinal non-Hodgkin's lymphoma: A clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG)
|Leukemia & lymphoma/Leukemia and lymphoma|2006|160